QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: dmd.106.010975v1 34/12/1945    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Bihorel, S. Articles by Scherrmann, J.-M. Search for Related Content PubMed PubMed Citation Articles by Bihorel, S. Articles by Scherrmann, J.-M.

SHORT COMMUNICATION

Influence of Hydroxyurea On Imatinib Mesylate (Gleevec) Transport at the Mouse Blood-Brain Barrier

Institut National de la Santé et de la Recherche Médicale, INSERM U 705, Université Paris 7, and Unité Mixte Recherche, Centre National de la Recherche Scientifique, CNRS 7157, Université Paris 5, Hôpital Fernand Widal, and Faculté de Pharmacie, Université Paris 5, Paris, France (S.B., J.-M.S.); and Department of Drug Metabolism and Pharmacokinetics, Novartis Pharma A.G., Basel, Switzerland (C.M., G.G., M.L.)

The combination of imatinib mesylate and hydroxyurea provides a therapeutic benefit in patients with glioblastoma, although each drug is not effective when used alone. The increase of brain delivery of one or both drugs has been suggested to be a potential cause of this therapeutic benefit. The cross-influence of hydroxyurea and imatinib on their respective brain distribution was examined in mice and rats. We used in situ brain perfusion in mice to determine whether these two drugs have an influence on their respective initial transport across the blood-brain barrier. The brain penetration of hydroxyurea, assessed by its brain uptake clearance, K_net, was low in mice (0.10 µl/g/s) and not modified by coperfusion of imatinib (0.5–500 µM). Likewise, the brain penetration of imatinib was low (K_net, 1.39 ± 0.17 µl/g/s) and not modified by direct coperfusion of hydroxyurea (0.2–1000 µM) or by intravenous pretreatment with 15 or 1000 mg/kg hydroxyurea. We also examined a potential time-dependent influence of hydroxyurea on imatinib brain distribution after sustained subcutaneous administration in rats using an implantable osmotic pump. The brain penetration of imatinib in rats increased with time, 1.6-fold (p < 0.01) after 7 and 14 days' infusion of imatinib (3 mg/day) with or without hydroxyurea (15 mg/day), and was not influenced by hydroxyurea. The results of these two sets of experiments indicate that hydroxyurea has no significant influence on the brain distribution of imatinib in mice and rats.